Risk of Cancer Following Hospitalization for Type 2 Diabetes

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2010 May 19

PMID 20479278

Citations 90

Authors

Kari Hemminki

Xinjun Li

Jan Sundquist

Kristina Sundquist

Affiliations

Soon will be listed here.

Abstract

Objectives: Cancer and type 2 diabetes (T2D) are two common diseases that may share risk factors. We aimed at determining subsequent cancer risks in patients hospitalized for T2D in Sweden.

Methods: T2D patients were obtained from the nationwide Hospital Discharge Register; cancers were recorded from the Swedish Cancer Registry. Standardized incidence ratios (SIRs) were calculated for cancer following last hospitalization for T2D. The comparison group was the general Swedish population.

Results: The number of hospitalized T2D patients from 1964 to 2007 was 125,126, of whom 26,641 had an affected family member. Altogether 24 cancers showed an elevated risk when follow-up was started after the last hospitalization. The highest SIRs were for pancreatic (6.08) and liver (4.25) cancers. The incidences of these cancers were even elevated when follow-up was started 5 years after the last hospitalization for T2D, with primary liver cancer showing the highest SIR of 4.66. Also increased were the incidences of upper aerodigestive tract, esophageal, colon, rectal, pancreatic, lung, cervical, endometrial, ovarian, and kidney cancers. Prostate cancer showed a lower risk. Familial T2D patients showed no exceptional elevated cancer risks but their prostate cancer and melanoma risks were lower.

Conclusions: This study, covering approximately one half of Swedish T2D patients, showed an elevated risk for several cancers after hospitalization for T2D, probably indicating the profound metabolic disturbances of the underlying disease. The highest risks were found for liver and pancreatic cancers. No excess cancer risks were observed in familial diabetics. The lower risk for prostate cancer remains intriguing.

Citing Articles

Genetic association of type 2 diabetes and antidiabetic drug target with skin cancer.

Zhao J, Zhang Y, Li J, Li Q, Teng Z Front Med (Lausanne). 2024; 11:1445853.

PMID: 39640975 PMC: 11617162. DOI: 10.3389/fmed.2024.1445853.

High Fat Mass Index is Associated with Endometrial Hyperplasia in Polycystic Ovary Syndrome Patients: A Retrospective Study.

Kuai D, Li M, He L, Li X, He Y, Liu S Int J Womens Health. 2024; 16:2065-2075.

PMID: 39640509 PMC: 11618852. DOI: 10.2147/IJWH.S491443.

Molecular Secrets Revealed: How Diabetes may be Paving the Way for Leukemia.

Goleij P, Tabari M, Ahmed A, Mohamed L, Saleh G, Abdu Hassan M Curr Treat Options Oncol. 2024; 25(12):1563-1579.

PMID: 39585587 DOI: 10.1007/s11864-024-01281-6.

Risk of bladder cancer in patients with type 2 diabetes mellitus: a retrospective population-based cohort study in Lithuania.

Ladukas A, Patasius A, Kincius M, Drevinskaite M, Jonusas J, Linkeviciute-Ulinskiene D Cancer Causes Control. 2024; 36(1):21-25.

PMID: 39305342 PMC: 11761827. DOI: 10.1007/s10552-024-01911-2.

Melanoma risk, tumour stage, and melanoma-specific mortality in individuals with diabetes: a systematic review and meta-analysis.

Tonder J, Bonnelykke-Behrndtz M, Laurberg T, Rossell E, Sollie M BMC Cancer. 2024; 24(1):812.

PMID: 38972968 PMC: 11229239. DOI: 10.1186/s12885-024-12598-8.

References

Cornier M, Dabelea D, Hernandez T, Lindstrom R, Steig A, Stob N . The metabolic syndrome. Endocr Rev. 2008; 29(7):777-822. PMC: 5393149. DOI: 10.1210/er.2008-0024. View

Coughlin S, Calle E, Teras L, Petrelli J, Thun M . Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004; 159(12):1160-7. DOI: 10.1093/aje/kwh161. View

Hemminki K, Vaittinen P, Dong C, Easton D . Sibling risks in cancer: clues to recessive or X-linked genes?. Br J Cancer. 2001; 84(3):388-91. PMC: 2363751. DOI: 10.1054/bjoc.2000.1585. View

Ringborg A, Lindgren P, Martinell M, Yin D, Schon S, Stalhammar J . Prevalence and incidence of Type 2 diabetes and its complications 1996-2003--estimates from a Swedish population-based study. Diabet Med. 2008; 25(10):1178-86. DOI: 10.1111/j.1464-5491.2008.02541.x. View

Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin J, Fraumeni J . A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control. 2001; 12(1):13-21. DOI: 10.1023/a:1008995217664. View

Ji J, Shu X, Li X, Sundquist K, Sundquist J, Hemminki K . Cancer risk in hospitalised asthma patients. Br J Cancer. 2009; 100(5):829-33. PMC: 2653753. DOI: 10.1038/sj.bjc.6604890. View

Carlsson S, Midthjell K, Grill V . Influence of family history of diabetes on incidence and prevalence of latent autoimmune diabetes of the adult: results from the Nord-Trøndelag Health Study. Diabetes Care. 2007; 30(12):3040-5. DOI: 10.2337/dc07-0718. View

Doria A, Patti M, Kahn C . The emerging genetic architecture of type 2 diabetes. Cell Metab. 2008; 8(3):186-200. PMC: 4267677. DOI: 10.1016/j.cmet.2008.08.006. View

Bell C, Walley A, Froguel P . The genetics of human obesity. Nat Rev Genet. 2005; 6(3):221-34. DOI: 10.1038/nrg1556. View

10.

Muoio D, Newgard C . Mechanisms of disease:Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol. 2008; 9(3):193-205. DOI: 10.1038/nrm2327. View

11.

Rousseau M, Parent M, Pollak M, Siemiatycki J . Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer. 2005; 118(8):2105-9. DOI: 10.1002/ijc.21600. View

12.

Carlsson S, Hammar N, Grill V . Alcohol consumption and type 2 diabetes Meta-analysis of epidemiological studies indicates a U-shaped relationship. Diabetologia. 2005; 48(6):1051-4. DOI: 10.1007/s00125-005-1768-5. View

13.

Hemminki K, Li X, Sundquist K, Sundquist J . Familial risks for type 2 diabetes in Sweden. Diabetes Care. 2009; 33(2):293-7. PMC: 2809269. DOI: 10.2337/dc09-0947. View

14.

Werny D, Saraiya M, Gregg E . Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol. 2006; 164(10):978-83. DOI: 10.1093/aje/kwj311. View

15.

Ji J, Shu X, Li X, Sundquist K, Sundquist J, Hemminki K . Cancer risk in hospitalized sarcoidosis patients: a follow-up study in Sweden. Ann Oncol. 2009; 20(6):1121-6. DOI: 10.1093/annonc/mdn767. View

16.

Ridderstrale M, Groop L . Genetic dissection of type 2 diabetes. Mol Cell Endocrinol. 2008; 297(1-2):10-7. DOI: 10.1016/j.mce.2008.10.002. View

17.

Eliasson B, Cederholm J, Nilsson P, Gudbjornsdottir S . The gap between guidelines and reality: Type 2 diabetes in a National Diabetes Register 1996-2003. Diabet Med. 2005; 22(10):1420-6. DOI: 10.1111/j.1464-5491.2005.01648.x. View

18.

Hemminki K, Li X, Sundquist J, Sundquist K . Cancer risks in Crohn disease patients. Ann Oncol. 2008; 20(3):574-80. DOI: 10.1093/annonc/mdn595. View

19.

Gudbjornsdottir S, Cederholm J, Nilsson P, Eliasson B . The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care. 2003; 26(4):1270-6. DOI: 10.2337/diacare.26.4.1270. View

20.

Adeghate E, Schattner P, Dunn E . An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci. 2006; 1084:1-29. DOI: 10.1196/annals.1372.029. View